NUVL
Price
$107.70
Change
+$6.53 (+6.45%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
7.86B
49 days until earnings call
Intraday BUY SELL Signals
PHVS
Price
$25.70
Change
-$0.30 (-1.15%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
1.69B
90 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NUVL vs PHVS

Header iconNUVL vs PHVS Comparison
Open Charts NUVL vs PHVSBanner chart's image
Nuvalent
Price$107.70
Change+$6.53 (+6.45%)
Volume$9.65K
Capitalization7.86B
Pharvaris
Price$25.70
Change-$0.30 (-1.15%)
Volume$5.88K
Capitalization1.69B
NUVL vs PHVS Comparison Chart in %
NUVL
Daily Signal:
Gain/Loss:
PHVS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NUVL vs. PHVS commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NUVL is a Hold and PHVS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (NUVL: $101.17 vs. PHVS: $26.00)
Brand notoriety: NUVL and PHVS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NUVL: 88% vs. PHVS: 48%
Market capitalization -- NUVL: $7.86B vs. PHVS: $1.69B
NUVL [@Biotechnology] is valued at $7.86B. PHVS’s [@Biotechnology] market capitalization is $1.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $115.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NUVL’s FA Score shows that 0 FA rating(s) are green whilePHVS’s FA Score has 1 green FA rating(s).

  • NUVL’s FA Score: 0 green, 5 red.
  • PHVS’s FA Score: 1 green, 4 red.
According to our system of comparison, both NUVL and PHVS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NUVL’s TA Score shows that 2 TA indicator(s) are bullish while PHVS’s TA Score has 5 bullish TA indicator(s).

  • NUVL’s TA Score: 2 bullish, 7 bearish.
  • PHVS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, PHVS is a better buy in the short-term than NUVL.

Price Growth

NUVL (@Biotechnology) experienced а +4.08% price change this week, while PHVS (@Biotechnology) price change was +8.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

NUVL is expected to report earnings on Mar 04, 2026.

PHVS is expected to report earnings on Apr 14, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($7.86B) has a higher market cap than PHVS($1.69B). NUVL YTD gains are higher at: 0.577 vs. PHVS (-6.306). PHVS has higher annual earnings (EBITDA): -166.91M vs. NUVL (-398.38M). NUVL has more cash in the bank: 943M vs. PHVS (329M). NUVL (0) and PHVS (0) have equivalent revenues.
NUVLPHVSNUVL / PHVS
Capitalization7.86B1.69B465%
EBITDA-398.38M-166.91M239%
Gain YTD0.577-6.306-9%
P/E RatioN/AN/A-
Revenue00-
Total Cash943M329M287%
Total DebtN/A579K-
TECHNICAL ANALYSIS
Technical Analysis
NUVLPHVS
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 13 days ago
83%
Bullish Trend 3 days ago
78%
Declines
ODDS (%)
Bearish Trend 16 days ago
77%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
NUVL
Daily Signal:
Gain/Loss:
PHVS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KMKYX80.571.43
+1.81%
Kinetics Market Opportunities Inst
GRESX8.280.05
+0.61%
Goldman Sachs Real Estate Securities Svc
PMPRX15.640.04
+0.26%
Principal MidCap Value I R3
PRSCX59.43-0.01
-0.02%
T. Rowe Price Science & Tech
DDIAX15.81-0.02
-0.13%
Nomura Wealth Builder A

PHVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHVS has been loosely correlated with MGTX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if PHVS jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHVS
1D Price
Change %
PHVS100%
-0.38%
MGTX - PHVS
37%
Loosely correlated
+1.93%
NUVL - PHVS
35%
Loosely correlated
+2.03%
INKT - PHVS
35%
Loosely correlated
-1.67%
BEAM - PHVS
34%
Loosely correlated
+2.55%
DSGN - PHVS
33%
Loosely correlated
+4.93%
More